Search results
Showing 251 to 298 of 298 results for breast cancer
In development [GID-TA10919] Expected publication date: TBC
Breast cancer (metastatic) -trastuzumab (as monotherapy and in combination with a taxane) [ID345]
Discontinued [GID-TAG417]
Atezolizumab with paclitaxel for untreated advanced triple-negative breast cancer [ID2705]
Discontinued [GID-TA10570]
Breast cancer (locally advanced or metastatic) - ixabepilone [ID377]
Discontinued [GID-TAG403]
Neratinib for treating HER2-positive breast cancer after 2 therapies [ID1381]
Discontinued [GID-TA10539]
Triptorelin for the adjuvant treatment of early breast cancer in premenopausal women [ID976]
Discontinued [GID-TA11261]
Breast cancer (HER2-negative, BRCA-mutation, unresectable) - niraparib [ID1084]
Discontinued [GID-TA11178]
Entinostat for treating hormone receptor-positive breast cancer after hormonal therapy [ID1260]
Discontinued [GID-TA10309]
Awaiting development [GID-TA11110] Expected publication date: TBC
Awaiting development [GID-TA10960] Expected publication date: TBC
Awaiting development [GID-TA11089] Expected publication date: TBC
Awaiting development [GID-TA11339] Expected publication date: TBC
In development [GID-TA10261] Expected publication date: TBC
Veliparib in combination for treating BRCA-positive, HER2-negative breast advanced cancer [ID1404]
Discontinued [GID-TA10327]
Pembrolizumab for previously treated metastatic triple negative breast cancer [ID1246]
Discontinued [GID-TA10295]
Awaiting development [GID-TA11403] Expected publication date: TBC
All NICE products on breast cancer. Includes any guidance, advice and quality standards.
Awaiting development [GID-TA11165] Expected publication date: TBC
Awaiting development [GID-TA11273] Expected publication date: TBC
Awaiting development [GID-TA11342] Expected publication date: TBC
Awaiting development [GID-TA11535] Expected publication date: TBC
In development [GID-NG10415] Expected publication date: TBC
Awaiting development [GID-TA11231] Expected publication date: TBC
Image-guided high intensity focused ultrasound to treat breast cancer
Register an interest in this interventional procedure ...
In development [GID-TA11402] Expected publication date: TBC
In development [GID-TA11400] Expected publication date: TBC
Capivasertib with paclitaxel for untreated metastatic triple-negative breast cancer [ID6383]
Awaiting development [GID-TA11411] Expected publication date: TBC
We are listening to your views on this NICE guideline. Comments close 19 April 2024.
Awaiting development [GID-TA11519] Expected publication date: TBC
In development [GID-TA11513] Expected publication date: TBC
Awaiting development [GID-TA11487] Expected publication date: TBC
In development [GID-TA10813] Expected publication date: 15 May 2024
In development [GID-TA11514] Expected publication date: TBC
In development [GID-NG10419] Expected publication date: 31 March 2025
Sacituzumab govitecan for untreated PD-L1-negative triple-negative advanced breast cancer ID6433
Awaiting development [GID-TA11489] Expected publication date: TBC
In development [GID-TA11263] Expected publication date: TBC
In development [GID-TA11439] Expected publication date: TBC
In development [GID-TA11090] Expected publication date: TBC
In development [GID-TA11318] Expected publication date: TBC
In development [GID-DG10075] Expected publication date: 09 May 2024